Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 1

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06727058 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development. The duration per participant will be approximately 13 months.

Conditions Studied

Interventions

  • OTHER Placebo
  • BIOLOGICAL Pandemic flu H5 mRNA vaccine

Study Locations (14)

Florida

  • Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400002 — DeLand
  • ARSN-Lakeland CRU- Site Number : 8400006 — Lakeland
  • Accel Research Sites - St. Petersburg- Site Number : 8400004 — Largo

Georgia

  • Atlanta Clinical Research Center- Site Number : 8400007 — Atlanta
  • Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400003 — Decatur

Nebraska

  • Velocity Clinical Research - Norfolk- Site Number : 8400015 — Norfolk
  • Velocity Clinical Research - Omaha- Site Number : 8400012 — Omaha

California

  • Velocity Clinical Research - San Diego- Site Number : 8400013 — La Mesa

Michigan

  • QUEST Research Institute- Site Number : 8400014 — Bingham Farms

Ohio

  • Velocity Clinical Research - Springdale- Site Number : 8400010 — Cincinnati

South Carolina

  • Coastal Carolina Research Center - North Charleston- Site Number : 8400001 — North Charleston

Texas

  • Olympus Clinical Research - Sugar Land- Site Number : 8400009 — Sugar Land

Trial Details

FieldValue
Enrollment Target 276 participants
Start Date 2024-12-09
Est. Completion 2026-03-31
Phase Phase 1

Sponsor

Sanofi Pasteur, a Sanofi Company

43 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06727058

The ClinicalTrials.gov registry entry for NCT06727058 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 43 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Influenza Immunization appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06727058 reports 14 study locations spanning 10 distinct geographic areas — top geographies include Florida, Georgia, Nebraska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06727058 about?

NCT06727058 is a clinical study titled "Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older". The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development. The duration per participan...

What is the current status of trial NCT06727058?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2024-12-09. Estimated completion is 2026-03-31.

What conditions does trial NCT06727058 study?

This clinical trial studies the following conditions: Influenza Immunization. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06727058?

The interventions under investigation include: Placebo (OTHER), Pandemic flu H5 mRNA vaccine (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06727058?

This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 43 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06727058 being conducted?

This trial has 14 study locations across California, Florida, Georgia, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial